Trade Sarepta Therapeutics, Inc. - SRPT CFD
Add to favourite- Summary
- Historical Data
| Spread | 1.40 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 116.93 |
| Open | 116.86 |
| 1-Year Change | -8.23% |
| Day's Range | 116.86 - 124.67 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 123.61 | 7.22 | 6.20% | 116.39 | 124.85 | 115.68 |
| Apr 23, 2024 | 116.93 | 0.84 | 0.72% | 116.09 | 119.79 | 116.09 |
| Apr 22, 2024 | 116.83 | 1.89 | 1.64% | 114.94 | 118.24 | 114.15 |
| Apr 19, 2024 | 115.47 | -0.18 | -0.16% | 115.65 | 117.41 | 114.09 |
| Apr 18, 2024 | 116.38 | -0.13 | -0.11% | 116.51 | 118.71 | 115.59 |
| Apr 17, 2024 | 117.68 | 1.97 | 1.70% | 115.71 | 118.92 | 115.40 |
| Apr 16, 2024 | 116.69 | -0.63 | -0.54% | 117.32 | 118.36 | 116.69 |
| Apr 15, 2024 | 117.73 | -3.28 | -2.71% | 121.01 | 122.00 | 117.41 |
| Apr 12, 2024 | 122.80 | 0.86 | 0.71% | 121.94 | 124.64 | 121.37 |
| Apr 11, 2024 | 124.29 | -1.51 | -1.20% | 125.80 | 126.66 | 123.20 |
| Apr 10, 2024 | 126.13 | 3.40 | 2.77% | 122.73 | 126.31 | 122.59 |
| Apr 9, 2024 | 126.14 | 0.49 | 0.39% | 125.65 | 127.21 | 125.18 |
| Apr 8, 2024 | 126.27 | 1.81 | 1.45% | 124.46 | 126.45 | 123.70 |
| Apr 5, 2024 | 125.45 | 0.64 | 0.51% | 124.81 | 127.24 | 122.68 |
| Apr 4, 2024 | 125.49 | -0.86 | -0.68% | 126.35 | 127.76 | 124.71 |
| Apr 3, 2024 | 126.78 | 2.32 | 1.86% | 124.46 | 128.40 | 124.46 |
| Apr 2, 2024 | 126.88 | 0.18 | 0.14% | 126.70 | 128.64 | 125.68 |
| Apr 1, 2024 | 128.35 | 1.44 | 1.13% | 126.91 | 128.98 | 126.01 |
| Mar 28, 2024 | 128.61 | -0.71 | -0.55% | 129.32 | 130.61 | 127.59 |
| Mar 27, 2024 | 130.03 | 2.05 | 1.60% | 127.98 | 130.19 | 126.76 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sarepta Company profile
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com